In Nucleic Acids Research this week: updated Aspergillus niger genome annotation, high-throughput sequencing strategy for profiling RNA structure, and more.
The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.
The company aims to position its platform as a validation tool for CRISPR-based therapeutics, while continuing to grow in the oncology space.
In a set of new studies, members of an international team mapped gene variation, expression, and regulatory interactions in developing and adult human brains.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The life science research tools firm is offering 8,150,000 shares of its common stock at a price of $6.75 per share for gross proceeds of about $55 million.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
In Science this week: single-cell analysis of colorectal cancers finds genome-wide demethylation patterns, and more.
The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.
Researchers identified immune activity changes in first-trimester placenta and decidua samples profiled through single-cell RNA sequencing.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.